Takehiro Okumura Ph.D. Head of Quality, Alloy Cell Therapies

In his current role, he leads the global quality and regulatory strategy for cell therapies at Alloy Therapeutics, while also driving business expansion in Japan as General Manager of Alloy Therapeutics Japan.

He has over 25 years of experience in the pharmaceutical industry, overseeing quality assurance from R&D to commercialization for diverse modalities, including small molecules, biologics, cell & gene therapy, and medical devices. Most recently, he built the cell therapy quality function from scratch at Takeda in both Japan and the U.S.. There, he successfully supported multiple novel autologous CAR-T and allogeneic CAR-NK therapy programs to achieve First-in-Human (FIH) trials.

At the PDA, he serves as a board member on the ATMP Advisory Board—the sole member from the Asia region—and as Co-Chair of the ATMP Interest Group.